NOV Inc.(NOV)Earnings, Financials & Key RatiosNOV Inc. (NOV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to maintain positive free cash flow, which reached a negative $91 million in 2026Q1, combined with a 2.4% revenue decline, suggests significant headwinds to near-term earnings growth.
NOV Inc. (NOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
NOV Inc. (NOV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 27, 2026 | $0.15vs $0.17-11.8% | $2.1Bvs $2.1B-0.1% |
| Q1 2026 | Feb 4, 2026 | $0.02vs $0.25-92.0% | $2.3Bvs $2.2B+5.0% |
| Q4 2025 | Oct 27, 2025 | $0.11vs $0.24-54.2% | $2.2Bvs $2.2B+0.4% |
| Q3 2025 | Jul 28, 2025 | $0.29vs $0.30-3.3% | $2.2Bvs $2.1B+3.6% |
Recent stock market news and headlines for NOV Inc. (NOV)
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).
Key metrics vs top competitors for NOV Inc. (NOV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.28 | $6.59B | 46.87 | -1.42% | 1.66% | 2.27% | 2.77% | |
| $54.47 | $54.02B | 20.95 | -0.34% | 11.17% | 16.13% | — | |
| $33.79 | $28.23B | 22.53 | -3.31% | 6.95% | 14.59% | — | |
| $46.42 | $69.4B | 19.75 | -1.6% | 9.2% | 12.82% | — | |
| $23.66 | $3.83B | 26.58 | -7.16% | 3.71% | 7.39% | — | |
| $45.01 | $118.13M | 5.20 | 13.64% | 10.76% | 14.37% | — |
NOV Inc. (NOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NOV Inc. (NOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 28, 2026·SEC
Apr 15, 2026·SEC
Mar 18, 2026·SEC
Get notified when NOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NOV Inc. (NOV) stock FAQ — growth, dividends, profitability & financials explained
NOV Inc. (NOV) reported $8.69B in revenue for fiscal year 2025. This represents a 1041% increase from $761.8M in 1996.
NOV Inc. (NOV) saw revenue decline by 1.4% over the past year.
Yes, NOV Inc. (NOV) is profitable, generating $91.0M in net income for fiscal year 2025 (1.7% net margin).
Yes, NOV Inc. (NOV) pays a dividend with a yield of 2.77%. This makes it attractive for income-focused investors.
NOV Inc. (NOV) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.
NOV Inc. (NOV) generated $734.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
